P/B
2,7
Yarrow Bioscience
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
$59.5M
Market Cap • 10/2/2026
2011
(15 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
123,4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
8,3
EPS
—
Market Cap
Market Cap
59,5M
EV
36,5M
EV/Revenue
75,8
EV/EBITDA
-0,9
EV/EBIT
-0,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-764,2M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
2041,1%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-43,1%
CAGR Op. Income 5Y
-21,6%
CAGR Net Income 5Y
-32,6%
CAGR EPS 5Y
-52,3%
CAGR OCF 5Y
-26,3%
Leverage
N.D./EBITDA
0,6
Debt/Equity
0%
Current Ratio
15,3
Quick Ratio
14,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!